Pembrolizumab In Central Nervous System Metastases
Фаза 2
Идёт, набор закрыт
NCT02886585
| Заболевание | Brain Metastases |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Massachusetts General Hospital |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 101 участн. |
|---|
| Вмешательство | Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery |
|---|
| Дата начала | 10.2016 |
|---|
| Дата завершения | 06.2027 |
|---|
| Публикация результатов | 26.06.2026 |
|---|
Кратко
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Intracranial Benefit Rate (Cohorts A and B)
44 months · percentage of patients
| Previously Untreated Brain Metastases-Cohort A | 33.3 percentage of patients |
|---|
| Progressive Brain Metastases-Cohort B | 43.8 percentage of patients |
|---|
Overall Survival at Three Months (Cohort C)
3 Months · proportion of patients
| Neoplastic Meningitis-Cohort C | 0.60 proportion of patients |
|---|
Extracranial Overall Response Rate (Cohort D)
Data collection is ongoing for this objective. The longest time a single patient has been followed for this measure is 6 years.
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.